News Articles and Montana BioScience Alliance Newsletters
Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray) are indicated for the treatment of acute migraine in adults. Strategic acquisition helps build Tonix’s commercial capabilities and infrastructure ahead of potential launch of TNX-102 SL for the treatment of fibromyalgia.
Microbion Corporation has announced that the company has been selected to present a poster highlighting the results from an E. coli CRISPR/Cas gene expression knockdown study characterizing pravibismane’s mechanism of action at the ASM Microbe Conference to be held in Houston, TX from June 15-19th, 2023.
Montana State University Extension and the Montana Department of Agriculture were recently announced as partners in a $30 million U.S. Department of Agriculture effort to establish a regional center to create opportunities for food producers and increase food security.
TNX-4300’s Mechanism of Restoring Neuroplasticity Supports Development as a First-in-Class Oral Therapy for Depression, Bipolar Disorder, Alzheimer’s Disease and Parkinson’s Disease
Extends patent protection for Microbion’s proprietary inhaled pravibismane for the treatment of pulmonary infections to 2039.
The NIA is accepting applications for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) funding. Learn more about these open opportunities. The next deadline to apply is January 5, 2024, unless otherwise noted.
The Senate has voted to confirm President Joe Biden’s pick to run the National Institutes of Health (NIH), Dr. Monica Bertagnolli, filling the director spot at the country’s top medical research agency after a vacancy of almost two years.
Updates from product development and small business programs
Are you working to develop an innovative cancer technology? Take a step forward in your commercialization journey through the newly released FY2024 SBIR Contract Solicitation! This funding opportunity aims to provide early-stage funding to small businesses that are developing cancer technologies in areas defined by the National Cancer Institute.
The U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer’s Disease, to traditional approval following a determination that a confirmatory trial verified clinical benefit.